Choroidal neovascularization (CNV) is an abnormal pathological state where new blood vessels develop abnormally beneath the retina. It is primarily found in the choroid, a vascular layer situated between the retina and the sclera of the eye.
Although age-related macular degeneration (AMD) is the most prevalent cause of this condition, CNV can also arise from other retinal disorders or ocular trauma.
In a healthy eye, the choroid provides necessary oxygen and nutrients to the retina. However, in CNV, the newly formed blood vessels are fragile and prone to leakage, leading to fluid accumulation and bleeding in the retina.
Epidemiology
Prevalence: CNV is most commonly associated with AMD, particularly the neovascular or “wet” form. AMD affects primarily older individuals, and the prevalence of CNV increases with age. by the published data of systematic & meta analysis 2014, the overall prevalence of any AMD was estimated to be around 8.7% globally, with the neovascular form accounting for approximately 10% of all AMD cases.
Risk Factors: The primary risk factor for CNV is age, as AMD and other CNV-associated conditions are more prevalent in older individuals. Other factors that increase the risk of CNV include:
Smoking: Smoking has been consistently identified as a modifiable risk factor for AMD and CNV. Smokers have a higher risk of developing CNV compared to nonsmokers.
Genetics: Variations in genes involved in inflammation, lipid metabolism, and angiogenesis have been associated with an increased risk of CNV.
Race and Ethnicity: Some studies have suggested that race and ethnicity may influence the risk of developing CNV. For example, individuals of European descent have a higher prevalence of CNV associated with AMD compared to other racial/ethnic groups.
Ocular Factors: Ocular conditions such as pathologic myopia, retinal dystrophies, and previous ocular trauma are associated with an increased risk of CNV.
Anatomy
Pathophysiology
Inflammation: In the early stages of CNV, there is an inflammatory response within the choroid and retinal pigment epithelium (RPE). This can be triggered by various factors, including oxidative stress, genetic predisposition, and immune dysregulation.
Angiogenesis: In CNV, angiogenesis occurs when the balance between pro-angiogenic and anti-angiogenic factors is disrupted. The main driver of angiogenesis in CNV is VEGF. VEGF is released by the RPE and other cells in response to hypoxia and inflammation.
Vascular Permeability: CNV is also associated with increased vascular permeability, which results in the leakage of fluid and blood into the subretinal space. VEGF plays a significant role in increasing vascular permeability by disrupting the tight junctions between endothelial cells, leading to the breakdown of the blood-retinal barrier.
Fibrosis and Scarring: As CNV progresses, there can be fibrosis and scarring in the subretinal space. Myofibroblasts, identified as fibroblast-like cells in an activated state, play a significant role in the synthesis of various components of the extracellular matrix, including collagen.
Etiology
Age-related changes: In AMD, which is the most common cause of CNV, aging plays a significant role. it is believed that oxidative stress, inflammation, and genetic factors contribute to the development of CNV in AMD.
Inflammation: Chronic inflammation in the eye can promote the development of CNV. Inflammatory mediators and immune cells can disrupt the normal balance of angiogenic factors and lead to the formation of new blood vessels.
Vascular endothelial growth factor (VEGF): VEGF is a critical factor in the development of CNV. Increased levels of VEGF have been observed in several ocular conditions associated with CNV.
Genetic factors: Genetic predisposition plays a role in the development of CNV. Certain gene variations have been associated with an increased risk of developing CNV in AMD. However, the specific genetic factors and their interactions are still being investigated.
Genetics
Prognostic Factors
Age: Older age is associated with a worse prognosis for CNV. Older patients may have a slower response to treatment and a higher risk of disease progression.
Size and location of CNV: Larger CNV lesions are generally associated with a worse prognosis. CNV located in the foveal region, which is responsible for central vision, also tends to have a poorer prognosis.
Visual acuity at baseline: Patients with better visual acuity at the time of diagnosis have a higher chance of achieving improved or stable vision with treatment.
Duration of symptoms: Longer duration of symptoms before treatment is associated with a poorer prognosis. Early detection and intervention can improve outcomes.
Clinical History
CLINICAL HISTORY
Age Group:
Choroidal neovascularization (CNV) can occur in individuals of different age groups, but it is more commonly associated with older adults.
CNV is a condition where abnormal blood vessels grow beneath the retina, which can lead to vision loss if left untreated.
Physical Examination
PHYSICAL EXAMINATION
Subretinal blood
Subretinal fluid
Lipid exudation
Retinal pigment epithelial detachment
Subretinal fibrosis (disciform scar)
Age group
Associated comorbidity
Associated Comorbidity or Activity:
Age-related macular degeneration (AMD): As mentioned earlier, CNV is most commonly associated with AMD, particularly the wet form. AMD is a degenerative eye disease that primarily affects older adults and is a major risk factor for CNV.
Genetic factors: Certain genetic variations have been identified as risk factors for developing CNV. Variants in genes such as complement factor H (CFH), complement factor B (CFB), and complement component 2 (C2) have been found to be associated with an increased risk of CNV.
Smoking: Research has established that smoking is a controllable risk element contributing to the emergence and advancement of CNV. Various studies have evidenced the heightened likelihood of developing AMD due to smoking, subsequently elevating the risk of CNV.
Associated activity
Acuity of presentation
Acuity of Presentation:
The acuity of presentation of choroidal neovascularization (CNV) can vary depending on various factors such as the underlying condition causing the CNV, the location and extent of the neovascularization, and individual patient characteristics.
In some cases, CNV may present suddenly and acutely, causing a rapid onset of symptoms. This can occur in conditions such as age-related macular degeneration (AMD), where CNV is a common complication. Patients may experience sudden onset of blurred or distorted vision, central scotoma (blind spot), or a sudden decrease in visual acuity.
Differential Diagnoses
DIFFERENTIAL DIAGNOSIS
Angioid streaks
Central serous chorioretinopathy (CSCR)
Ocular histoplasmosis syndrome (OHS)
Age-related macular degeneration (AMD)
Laboratory Studies
Imaging Studies
Procedures
Histologic Findings
Staging
Treatment Paradigm
TREATMENT PARADIGM
Modification of Environment:
Lifestyle modifications: To effectively manage CNV and lower the chances of its advancement, incorporating specific lifestyle alterations is crucial. These adjustments encompass giving up smoking, consuming a nutritious diet, maintaining an optimal weight, and engaging in regular physical activity. By adopting these modifications, individuals can promote their overall eye well-being and potentially decelerate the progression of CNV.
Protective eyewear and sun exposure: To prevent damage from ultraviolet (UV) rays, it is recommended to wear sunglasses with UV protection and a hat with a wide brim.
Regular eye examinations: Routine eye exams are crucial for the early detection and monitoring of CNV.
Administration of Pharmaceutical Agents with Drugs:
The most commonly used drugs for CNV are anti-VEGF agents, such as ranibizumab, bevacizumab, and aflibercept These medications function by impeding the development of atypical blood vessels and diminishing inflammation within the ocular region. They are typically administered through intravitreal injections, which involve injecting the drug directly into the vitreous cavity of the eye
Corticosteroids, such as triamcinolone acetonide and dexamethasone, are another class of drugs used in the treatment of CNV.
Photodynamic therapy (PDT) agents, such as verteporfin, are used in combination with laser treatment to selectively destroy abnormal blood vessels in the eye. These agents are typically administered intravenously.
Intervention with a Procedure:
Anti-vascular endothelial growth factor (anti-VEGF) injections: These medications block the action of VEGF, a protein responsible for the growth of abnormal blood vessels. Anti-VEGF injections help to reduce fluid leakage, prevent further blood vessel growth, and improve vision.
Photodynamic therapy (PDT): PDT involves the use of a light-activated drug called verteporfin. First, the medication is administered intravenously, followed by the utilization of a laser to target the specific region of the eye, activating the drug and causing damage to the abnormal blood vessels. PDT is sometimes used as a complementary therapy with anti-VEGF injections.
Laser photocoagulation: Laser photocoagulation is less commonly used today due to the availability of more advanced treatments like anti-VEGF therapy.
Surgical intervention: In some cases, when other treatments are not effective or feasible, surgery may be considered. Surgical options include removing the abnormal blood vessels, transplanting healthy tissue, or placing implants to stabilize the retina.
Phase of Management:
Diagnosis and Evaluation: The first step is to establish a diagnosis of CNV, which is typically done through a comprehensive eye examination. This may include visual acuity testing, dilated fundus examination, optical coherence tomography (OCT), fluorescein angiography (FA), and/or indocyanine green angiography (ICGA). These tests help identify the presence, location, and extent of CNV.
Treatment Selection: Once CNV is confirmed, the appropriate treatment option is determined. Common treatment options include anti-vascular endothelial growth factor (anti-VEGF) injections, photodynamic therapy (PDT), and laser photocoagulation.
Initial Treatment: The next phase involves initiating the selected treatment. Anti-VEGF injections, such as ranibizumab (Lucentis), aflibercept (Eylea), or bevacizumab (Avastin), are commonly used as first-line treatment for CNV.
Monitoring and Adjustments: Following the initial treatment, patients are regularly monitored to assess treatment response and disease progression. This monitoring typically involves regular follow-up visits, including visual acuity assessments and imaging tests (OCT, FA, or ICGA) to evaluate the anatomical and functional changes in the retina and choroid. Adjustments to the treatment plan, such as the frequency of injections or switching to a different medication, may be made based on the patient’s response.
by Stage
by Modality
Chemotherapy
Radiation Therapy
Surgical Interventions
Hormone Therapy
Immunotherapy
Hyperthermia
Photodynamic Therapy
Stem Cell Transplant
Targeted Therapy
Palliative Care
Medication
Future Trends
Media Gallary
References
Yeo NJY, Chan EJJ, Cheung C. Choroidal Neovascularization:
Mechanisms of Endothelial Dysfunction.ncbi.nlm.nih
Choroidal neovascularization (CNV) is an abnormal pathological state where new blood vessels develop abnormally beneath the retina. It is primarily found in the choroid, a vascular layer situated between the retina and the sclera of the eye.
Although age-related macular degeneration (AMD) is the most prevalent cause of this condition, CNV can also arise from other retinal disorders or ocular trauma.
In a healthy eye, the choroid provides necessary oxygen and nutrients to the retina. However, in CNV, the newly formed blood vessels are fragile and prone to leakage, leading to fluid accumulation and bleeding in the retina.
Prevalence: CNV is most commonly associated with AMD, particularly the neovascular or “wet” form. AMD affects primarily older individuals, and the prevalence of CNV increases with age. by the published data of systematic & meta analysis 2014, the overall prevalence of any AMD was estimated to be around 8.7% globally, with the neovascular form accounting for approximately 10% of all AMD cases.
Risk Factors: The primary risk factor for CNV is age, as AMD and other CNV-associated conditions are more prevalent in older individuals. Other factors that increase the risk of CNV include:
Smoking: Smoking has been consistently identified as a modifiable risk factor for AMD and CNV. Smokers have a higher risk of developing CNV compared to nonsmokers.
Genetics: Variations in genes involved in inflammation, lipid metabolism, and angiogenesis have been associated with an increased risk of CNV.
Race and Ethnicity: Some studies have suggested that race and ethnicity may influence the risk of developing CNV. For example, individuals of European descent have a higher prevalence of CNV associated with AMD compared to other racial/ethnic groups.
Ocular Factors: Ocular conditions such as pathologic myopia, retinal dystrophies, and previous ocular trauma are associated with an increased risk of CNV.
Inflammation: In the early stages of CNV, there is an inflammatory response within the choroid and retinal pigment epithelium (RPE). This can be triggered by various factors, including oxidative stress, genetic predisposition, and immune dysregulation.
Angiogenesis: In CNV, angiogenesis occurs when the balance between pro-angiogenic and anti-angiogenic factors is disrupted. The main driver of angiogenesis in CNV is VEGF. VEGF is released by the RPE and other cells in response to hypoxia and inflammation.
Vascular Permeability: CNV is also associated with increased vascular permeability, which results in the leakage of fluid and blood into the subretinal space. VEGF plays a significant role in increasing vascular permeability by disrupting the tight junctions between endothelial cells, leading to the breakdown of the blood-retinal barrier.
Fibrosis and Scarring: As CNV progresses, there can be fibrosis and scarring in the subretinal space. Myofibroblasts, identified as fibroblast-like cells in an activated state, play a significant role in the synthesis of various components of the extracellular matrix, including collagen.
Age-related changes: In AMD, which is the most common cause of CNV, aging plays a significant role. it is believed that oxidative stress, inflammation, and genetic factors contribute to the development of CNV in AMD.
Inflammation: Chronic inflammation in the eye can promote the development of CNV. Inflammatory mediators and immune cells can disrupt the normal balance of angiogenic factors and lead to the formation of new blood vessels.
Vascular endothelial growth factor (VEGF): VEGF is a critical factor in the development of CNV. Increased levels of VEGF have been observed in several ocular conditions associated with CNV.
Genetic factors: Genetic predisposition plays a role in the development of CNV. Certain gene variations have been associated with an increased risk of developing CNV in AMD. However, the specific genetic factors and their interactions are still being investigated.
Age: Older age is associated with a worse prognosis for CNV. Older patients may have a slower response to treatment and a higher risk of disease progression.
Size and location of CNV: Larger CNV lesions are generally associated with a worse prognosis. CNV located in the foveal region, which is responsible for central vision, also tends to have a poorer prognosis.
Visual acuity at baseline: Patients with better visual acuity at the time of diagnosis have a higher chance of achieving improved or stable vision with treatment.
Duration of symptoms: Longer duration of symptoms before treatment is associated with a poorer prognosis. Early detection and intervention can improve outcomes.
CLINICAL HISTORY
Age Group:
Choroidal neovascularization (CNV) can occur in individuals of different age groups, but it is more commonly associated with older adults.
CNV is a condition where abnormal blood vessels grow beneath the retina, which can lead to vision loss if left untreated.
PHYSICAL EXAMINATION
Subretinal blood
Subretinal fluid
Lipid exudation
Retinal pigment epithelial detachment
Subretinal fibrosis (disciform scar)
Associated Comorbidity or Activity:
Age-related macular degeneration (AMD): As mentioned earlier, CNV is most commonly associated with AMD, particularly the wet form. AMD is a degenerative eye disease that primarily affects older adults and is a major risk factor for CNV.
Genetic factors: Certain genetic variations have been identified as risk factors for developing CNV. Variants in genes such as complement factor H (CFH), complement factor B (CFB), and complement component 2 (C2) have been found to be associated with an increased risk of CNV.
Smoking: Research has established that smoking is a controllable risk element contributing to the emergence and advancement of CNV. Various studies have evidenced the heightened likelihood of developing AMD due to smoking, subsequently elevating the risk of CNV.
Acuity of Presentation:
The acuity of presentation of choroidal neovascularization (CNV) can vary depending on various factors such as the underlying condition causing the CNV, the location and extent of the neovascularization, and individual patient characteristics.
In some cases, CNV may present suddenly and acutely, causing a rapid onset of symptoms. This can occur in conditions such as age-related macular degeneration (AMD), where CNV is a common complication. Patients may experience sudden onset of blurred or distorted vision, central scotoma (blind spot), or a sudden decrease in visual acuity.
DIFFERENTIAL DIAGNOSIS
Angioid streaks
Central serous chorioretinopathy (CSCR)
Ocular histoplasmosis syndrome (OHS)
Age-related macular degeneration (AMD)
TREATMENT PARADIGM
Modification of Environment:
Lifestyle modifications: To effectively manage CNV and lower the chances of its advancement, incorporating specific lifestyle alterations is crucial. These adjustments encompass giving up smoking, consuming a nutritious diet, maintaining an optimal weight, and engaging in regular physical activity. By adopting these modifications, individuals can promote their overall eye well-being and potentially decelerate the progression of CNV.
Protective eyewear and sun exposure: To prevent damage from ultraviolet (UV) rays, it is recommended to wear sunglasses with UV protection and a hat with a wide brim.
Regular eye examinations: Routine eye exams are crucial for the early detection and monitoring of CNV.
Administration of Pharmaceutical Agents with Drugs:
The most commonly used drugs for CNV are anti-VEGF agents, such as ranibizumab, bevacizumab, and aflibercept These medications function by impeding the development of atypical blood vessels and diminishing inflammation within the ocular region. They are typically administered through intravitreal injections, which involve injecting the drug directly into the vitreous cavity of the eye
Corticosteroids, such as triamcinolone acetonide and dexamethasone, are another class of drugs used in the treatment of CNV.
Photodynamic therapy (PDT) agents, such as verteporfin, are used in combination with laser treatment to selectively destroy abnormal blood vessels in the eye. These agents are typically administered intravenously.
Intervention with a Procedure:
Anti-vascular endothelial growth factor (anti-VEGF) injections: These medications block the action of VEGF, a protein responsible for the growth of abnormal blood vessels. Anti-VEGF injections help to reduce fluid leakage, prevent further blood vessel growth, and improve vision.
Photodynamic therapy (PDT): PDT involves the use of a light-activated drug called verteporfin. First, the medication is administered intravenously, followed by the utilization of a laser to target the specific region of the eye, activating the drug and causing damage to the abnormal blood vessels. PDT is sometimes used as a complementary therapy with anti-VEGF injections.
Laser photocoagulation: Laser photocoagulation is less commonly used today due to the availability of more advanced treatments like anti-VEGF therapy.
Surgical intervention: In some cases, when other treatments are not effective or feasible, surgery may be considered. Surgical options include removing the abnormal blood vessels, transplanting healthy tissue, or placing implants to stabilize the retina.
Phase of Management:
Diagnosis and Evaluation: The first step is to establish a diagnosis of CNV, which is typically done through a comprehensive eye examination. This may include visual acuity testing, dilated fundus examination, optical coherence tomography (OCT), fluorescein angiography (FA), and/or indocyanine green angiography (ICGA). These tests help identify the presence, location, and extent of CNV.
Treatment Selection: Once CNV is confirmed, the appropriate treatment option is determined. Common treatment options include anti-vascular endothelial growth factor (anti-VEGF) injections, photodynamic therapy (PDT), and laser photocoagulation.
Initial Treatment: The next phase involves initiating the selected treatment. Anti-VEGF injections, such as ranibizumab (Lucentis), aflibercept (Eylea), or bevacizumab (Avastin), are commonly used as first-line treatment for CNV.
Monitoring and Adjustments: Following the initial treatment, patients are regularly monitored to assess treatment response and disease progression. This monitoring typically involves regular follow-up visits, including visual acuity assessments and imaging tests (OCT, FA, or ICGA) to evaluate the anatomical and functional changes in the retina and choroid. Adjustments to the treatment plan, such as the frequency of injections or switching to a different medication, may be made based on the patient’s response.
Yeo NJY, Chan EJJ, Cheung C. Choroidal Neovascularization:
Mechanisms of Endothelial Dysfunction.ncbi.nlm.nih
medtigo
Choroidal neovascularization
Updated :
September 6, 2023
Choroidal neovascularization (CNV) is an abnormal pathological state where new blood vessels develop abnormally beneath the retina. It is primarily found in the choroid, a vascular layer situated between the retina and the sclera of the eye.
Although age-related macular degeneration (AMD) is the most prevalent cause of this condition, CNV can also arise from other retinal disorders or ocular trauma.
In a healthy eye, the choroid provides necessary oxygen and nutrients to the retina. However, in CNV, the newly formed blood vessels are fragile and prone to leakage, leading to fluid accumulation and bleeding in the retina.
Prevalence: CNV is most commonly associated with AMD, particularly the neovascular or “wet” form. AMD affects primarily older individuals, and the prevalence of CNV increases with age. by the published data of systematic & meta analysis 2014, the overall prevalence of any AMD was estimated to be around 8.7% globally, with the neovascular form accounting for approximately 10% of all AMD cases.
Risk Factors: The primary risk factor for CNV is age, as AMD and other CNV-associated conditions are more prevalent in older individuals. Other factors that increase the risk of CNV include:
Smoking: Smoking has been consistently identified as a modifiable risk factor for AMD and CNV. Smokers have a higher risk of developing CNV compared to nonsmokers.
Genetics: Variations in genes involved in inflammation, lipid metabolism, and angiogenesis have been associated with an increased risk of CNV.
Race and Ethnicity: Some studies have suggested that race and ethnicity may influence the risk of developing CNV. For example, individuals of European descent have a higher prevalence of CNV associated with AMD compared to other racial/ethnic groups.
Ocular Factors: Ocular conditions such as pathologic myopia, retinal dystrophies, and previous ocular trauma are associated with an increased risk of CNV.
Inflammation: In the early stages of CNV, there is an inflammatory response within the choroid and retinal pigment epithelium (RPE). This can be triggered by various factors, including oxidative stress, genetic predisposition, and immune dysregulation.
Angiogenesis: In CNV, angiogenesis occurs when the balance between pro-angiogenic and anti-angiogenic factors is disrupted. The main driver of angiogenesis in CNV is VEGF. VEGF is released by the RPE and other cells in response to hypoxia and inflammation.
Vascular Permeability: CNV is also associated with increased vascular permeability, which results in the leakage of fluid and blood into the subretinal space. VEGF plays a significant role in increasing vascular permeability by disrupting the tight junctions between endothelial cells, leading to the breakdown of the blood-retinal barrier.
Fibrosis and Scarring: As CNV progresses, there can be fibrosis and scarring in the subretinal space. Myofibroblasts, identified as fibroblast-like cells in an activated state, play a significant role in the synthesis of various components of the extracellular matrix, including collagen.
Age-related changes: In AMD, which is the most common cause of CNV, aging plays a significant role. it is believed that oxidative stress, inflammation, and genetic factors contribute to the development of CNV in AMD.
Inflammation: Chronic inflammation in the eye can promote the development of CNV. Inflammatory mediators and immune cells can disrupt the normal balance of angiogenic factors and lead to the formation of new blood vessels.
Vascular endothelial growth factor (VEGF): VEGF is a critical factor in the development of CNV. Increased levels of VEGF have been observed in several ocular conditions associated with CNV.
Genetic factors: Genetic predisposition plays a role in the development of CNV. Certain gene variations have been associated with an increased risk of developing CNV in AMD. However, the specific genetic factors and their interactions are still being investigated.
Age: Older age is associated with a worse prognosis for CNV. Older patients may have a slower response to treatment and a higher risk of disease progression.
Size and location of CNV: Larger CNV lesions are generally associated with a worse prognosis. CNV located in the foveal region, which is responsible for central vision, also tends to have a poorer prognosis.
Visual acuity at baseline: Patients with better visual acuity at the time of diagnosis have a higher chance of achieving improved or stable vision with treatment.
Duration of symptoms: Longer duration of symptoms before treatment is associated with a poorer prognosis. Early detection and intervention can improve outcomes.
CLINICAL HISTORY
Age Group:
Choroidal neovascularization (CNV) can occur in individuals of different age groups, but it is more commonly associated with older adults.
CNV is a condition where abnormal blood vessels grow beneath the retina, which can lead to vision loss if left untreated.
PHYSICAL EXAMINATION
Subretinal blood
Subretinal fluid
Lipid exudation
Retinal pigment epithelial detachment
Subretinal fibrosis (disciform scar)
Associated Comorbidity or Activity:
Age-related macular degeneration (AMD): As mentioned earlier, CNV is most commonly associated with AMD, particularly the wet form. AMD is a degenerative eye disease that primarily affects older adults and is a major risk factor for CNV.
Genetic factors: Certain genetic variations have been identified as risk factors for developing CNV. Variants in genes such as complement factor H (CFH), complement factor B (CFB), and complement component 2 (C2) have been found to be associated with an increased risk of CNV.
Smoking: Research has established that smoking is a controllable risk element contributing to the emergence and advancement of CNV. Various studies have evidenced the heightened likelihood of developing AMD due to smoking, subsequently elevating the risk of CNV.
Acuity of Presentation:
The acuity of presentation of choroidal neovascularization (CNV) can vary depending on various factors such as the underlying condition causing the CNV, the location and extent of the neovascularization, and individual patient characteristics.
In some cases, CNV may present suddenly and acutely, causing a rapid onset of symptoms. This can occur in conditions such as age-related macular degeneration (AMD), where CNV is a common complication. Patients may experience sudden onset of blurred or distorted vision, central scotoma (blind spot), or a sudden decrease in visual acuity.
DIFFERENTIAL DIAGNOSIS
Angioid streaks
Central serous chorioretinopathy (CSCR)
Ocular histoplasmosis syndrome (OHS)
Age-related macular degeneration (AMD)
TREATMENT PARADIGM
Modification of Environment:
Lifestyle modifications: To effectively manage CNV and lower the chances of its advancement, incorporating specific lifestyle alterations is crucial. These adjustments encompass giving up smoking, consuming a nutritious diet, maintaining an optimal weight, and engaging in regular physical activity. By adopting these modifications, individuals can promote their overall eye well-being and potentially decelerate the progression of CNV.
Protective eyewear and sun exposure: To prevent damage from ultraviolet (UV) rays, it is recommended to wear sunglasses with UV protection and a hat with a wide brim.
Regular eye examinations: Routine eye exams are crucial for the early detection and monitoring of CNV.
Administration of Pharmaceutical Agents with Drugs:
The most commonly used drugs for CNV are anti-VEGF agents, such as ranibizumab, bevacizumab, and aflibercept These medications function by impeding the development of atypical blood vessels and diminishing inflammation within the ocular region. They are typically administered through intravitreal injections, which involve injecting the drug directly into the vitreous cavity of the eye
Corticosteroids, such as triamcinolone acetonide and dexamethasone, are another class of drugs used in the treatment of CNV.
Photodynamic therapy (PDT) agents, such as verteporfin, are used in combination with laser treatment to selectively destroy abnormal blood vessels in the eye. These agents are typically administered intravenously.
Intervention with a Procedure:
Anti-vascular endothelial growth factor (anti-VEGF) injections: These medications block the action of VEGF, a protein responsible for the growth of abnormal blood vessels. Anti-VEGF injections help to reduce fluid leakage, prevent further blood vessel growth, and improve vision.
Photodynamic therapy (PDT): PDT involves the use of a light-activated drug called verteporfin. First, the medication is administered intravenously, followed by the utilization of a laser to target the specific region of the eye, activating the drug and causing damage to the abnormal blood vessels. PDT is sometimes used as a complementary therapy with anti-VEGF injections.
Laser photocoagulation: Laser photocoagulation is less commonly used today due to the availability of more advanced treatments like anti-VEGF therapy.
Surgical intervention: In some cases, when other treatments are not effective or feasible, surgery may be considered. Surgical options include removing the abnormal blood vessels, transplanting healthy tissue, or placing implants to stabilize the retina.
Phase of Management:
Diagnosis and Evaluation: The first step is to establish a diagnosis of CNV, which is typically done through a comprehensive eye examination. This may include visual acuity testing, dilated fundus examination, optical coherence tomography (OCT), fluorescein angiography (FA), and/or indocyanine green angiography (ICGA). These tests help identify the presence, location, and extent of CNV.
Treatment Selection: Once CNV is confirmed, the appropriate treatment option is determined. Common treatment options include anti-vascular endothelial growth factor (anti-VEGF) injections, photodynamic therapy (PDT), and laser photocoagulation.
Initial Treatment: The next phase involves initiating the selected treatment. Anti-VEGF injections, such as ranibizumab (Lucentis), aflibercept (Eylea), or bevacizumab (Avastin), are commonly used as first-line treatment for CNV.
Monitoring and Adjustments: Following the initial treatment, patients are regularly monitored to assess treatment response and disease progression. This monitoring typically involves regular follow-up visits, including visual acuity assessments and imaging tests (OCT, FA, or ICGA) to evaluate the anatomical and functional changes in the retina and choroid. Adjustments to the treatment plan, such as the frequency of injections or switching to a different medication, may be made based on the patient’s response.
Yeo NJY, Chan EJJ, Cheung C. Choroidal Neovascularization:
Mechanisms of Endothelial Dysfunction.ncbi.nlm.nih
Loading...
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Digital Certificate PDF
On course completion, you will receive a full-sized presentation quality digital certificate.
medtigo Simulation
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
medtigo Points
medtigo points is our unique point redemption system created to award users for interacting on our site. These points can be redeemed for special discounts on the medtigo marketplace as well as towards the membership cost itself.
Community Forum post/reply = 5 points
*Redemption of points can occur only through the medtigo marketplace, courses, or simulation system. Money will not be credited to your bank account. 10 points = $1.
All Your Certificates in One Place
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
